Summary
• Salarius Pharmaceuticals (SLRX) stock rose 7.9% to $0.9389 in after-hours trading following a new collaboration announcement.
• The partnership with Texas Biomedical Research Institute focuses on testing influenza fusion inhibitors from its subsidiary, Decoy Therapeutics.
• Despite a 91.2% year-to-date decline, executives’ recent stock purchases indicate confidence in the company’s prospects.
Salarius Pharmaceuticals, Inc. (SLRX) is trading at $0.9389 in after-hours, reflecting a notable increase of 7.9% from its previous close of $0.8703. This uptick follows an announcement regarding a new collaboration aimed at advancing its research efforts.
Collaboration on Avian Flu Study
Earlier today, Salarius Pharmaceuticals announced a collaboration with the Texas Biomedical Research Institute to conduct in vitro testing of its influenza fusion inhibitors developed by its subsidiary, Decoy Therapeutics. These inhibitors, designed using the proprietary IMP 3 ACT™ platform, are noted for their promising binding characteristics to viral targets, which support their potential applications in treating influenza, including avian flu. The collaboration is aiming to leverage Salarius’ capabilities to create comprehensive antiviral therapies against various respiratory viruses, including COVID and RSV.
This partnership showcases Salarius’ readiness to address substantial global market demands and enhance its research capabilities, aligning with its strategic growth objectives.
Market and Technical Picture
The stock’s recent performance reflects significant volatility, with a year-to-date decline of approximately 91.2% and a quarterly performance drop of 71.4%. Despite the current rally, the stock’s 20-day simple moving average (SMA) indicates a substantial 42.7% deviation. The 14-day Relative Strength Index (RSI) stands at 24.74, suggesting potential oversold conditions, but this aligns with the stock’s broader trend, having struggled in the market for an extended period. The average volume over the last 10 days was 38,121, markedly lower than the 1,715,407 average over the past three months, indicating a potential increase in trading activity as interest in the stock grows.
Insider Transactions and Market Sentiment
Recent insider transactions also provide insight into the market’s sentiment surrounding Salarius. Significant purchases by executives, including 20,000 shares by the Executive VP of Finance and CFO Mark J. Rosenblum at $0.80 per share, suggest a level of confidence in the company’s future. Additionally, the stock maintains a “Buy” rating from analysts, reflecting an optimistic outlook despite its challenging performance over the last year.
Concluding Remarks
With today’s positive movement following the collaboration announcement, investors are likely to monitor how this engagement bolsters Salarius’ research capabilities and its positioning within the competitive biotech landscape. As the company is re-evaluating its strategic focuses, market participants will be observing the stock’s momentum closely as it heads into the next trading session.